Dear Editor,
A 42-year-old female presented with a right submandibular mass and was diagnosed with stage IVA grade II follicular lymphoma. After receiving multiple lines of treatment, (including CHOP, FMD, autologous transplant, rituximab, and yttrium-90-ibritumomab), she underwent an unrelated, human leukocyte antigen-mismatched (9/10), nonmyeloablative, allogeneic peripheral blood stem cell transplantation in partial remission December 29, 2006. Conditioning regimen consisted of fludarabine and melphalan [1] . Cyclosporin and mycophenolate mofetil were used as graft versus host disease (GVHD) prophylaxis. Patient and donor had Epstein-Barr virus (EBV) IgG antibodies. Complete chimerism was documented on day+28, remaining stable up to date. She developed grade II (skin III, gastrointestinal I) acute GVHD managed with metil prednisolone (2 mg/kg) and beclomethasone (2 mg/6 h). Signs and symptoms subsided on day+54, and steroids were tapered.
On day+100, she presented with a right inguinal mass. Positron emission tomography/computed tomography (PET/CT) scan showed right iliac (1.5×2.5 cm) and inguinal (3×1.5 cm) lymphadenopathies, the latter fluorodeoxyglucose avid (SUV10.5). Incisional biopsy of the right inguinal node showed diffuse large B-cell lymphoma (DLBCL) with a proliferation index of 90%; EBV was negative; qualitative polymerase chain reaction showed the presence of the BCL2/JH (Mbr) rearrangement; cytogenetics and fluorescent in situ hybridization detected the t(14;18) with no other added lesions; GeneScanning analysis and sequencing of the immunoglobulin chain gene rearrangement V K -Kde was identical to that detected at diagnosis confirming the re-appearance of the malignant clone and thus, the diagnosis of relapsed disease transformed to DLBCL (Fig. 1a) [2]. Flow cytometric analysis on lymphadenopathy cell suspensions identified a B-cell malignancy intermingled with a polyclonal T-cell population representing 42% of the cellularity; chimerism analysis (STR and GeneScanning) detected 42% of donor cells and 58% of patient cells (Fig. 1b) . Taken together, results can be explained by the presence in the sample of patientderived clonal B-cells together with infiltrating T-cell lymphocytes (TIL-T) of donor origin, findings suggestive of an active graft versus lymphoma effect.
Baseline immunosuppression was reduced, and she received four doses of single agent rituximab at a standard dose. Three months later, re-evaluation with PET/CT and bone marrow biopsy showed complete remission. She developed chronic GVHD affecting the gastrointestinal tract and joints (+874) and is currently taking tacrolimus and steroids at a low dose. Repeated follow-up imaging, including the most recent PET/CT scan (February 2009), showed no significant abnormalities. There is no evidence of disease in the last bone marrow assessment (March 2009).
In summary, our patient presented with a rapidly enlarging, PET positive, right inguinal node early postallotransplant. A post-transplant lymphoproliferative disorder was suspected, but an identical immunoglobulin chain gene rearrangement to that detected at diagnosis was identified, confirming the diagnosis of relapsed lymphoma transformed to DLBCL. The frequency of this entity is unknown since most studies do not specify/confirm histologies at relapse [3] [4] [5] [6] . Despite the poor prognosis of transformed follicular lymphoma [7] , our patient remains clinically and radiologically in complete remission on day +915 post-transplant. It is likely that rituximab and a GVL effect exerted by a TIL-T population and forced by reducing the immunosuppression influenced the outcome of our patient [8, 9] .
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